OVID THERAPEUTICS DL-,001 WKN: A2DQ8S ISIN: US6904691010 Kürzel: 1OT Forum: Aktien Thema: Hauptdiskussion
2,78 EUR
-1,77 %-0,05
3. Jun, 21:42:23 Uhr,
Lang & Schwarz
Kommentare 17
LkBerlin,
27.05.2020 16:11 Uhr
0
Etwas zu schnell gewachsen, darum heute kleiner Dämpfer, aber nach wie vor vielversprechendes Investment.
Schorsch11,
01.02.2020 15:03 Uhr
0
Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome
https://seekingalpha.com/pr/17561466?source=ansh $OVID
Schorsch11,
01.02.2020 10:50 Uhr
0
191 gelistete Patente
https://patentscope.wipo.int/search/en/result.jsf?_vid=P11-K63EZZ-31269
9 klinische Studien
https://clinicaltrials.gov/ct2/results?cond=&term=ovid+therapeutics+&cntry=&state=&city=&dist=
Schorsch11,
01.02.2020 10:49 Uhr
0
Cash: 37.9mio$
burn: 3.2mio$/month
reicht in Zusammenhang mit dem Oktober Offering bis Mitte 2021
Proforma cash of ~$71M(1); fully funded
through clinical data events
PRICE TO BOOK 5.71
MARKET CAP 172,139,162
SHARES 47,816,434
AV. DAILY VOLUME 721,785
Schorsch11,
01.02.2020 10:43 Uhr
0
RBC Capital analyst Brian Abrahams sees a favorable risk-reward for Ovid Therapeutics (NASDAQ:OVID) heading into next year.
The key data catalysts will be for lead programs OV101 and soticlestat.
Data for OV101 for FXS should report in Q1, and the pivotal Phase 3 trial for Angelman's Syndrome will report in mid-2020. Abrahams says "there are underappreciated signals of efficacy" for the latter indication that could provide a "low regulatory bar" for the disease.
The analyst thinks OV101 could generate $450M+ in "peak annual out-year revenue if successful." For soticlestat, he sees a near $400M out-year sales opportunity for refractory epilepsies.
RBC maintains an Outperform rating and $12 price target. OVID has a Very Bullish average Sell Side rating.
Schorsch11,
01.02.2020 10:43 Uhr
0
OV101 (gaboxadol) in Neurodevelopmental Disorders:
Topline Results From Pivotal Phase 3 NEPTUNE Trial in Angelman Syndrome Expected in Mid-2020
Results From Phase 2 Signal-Finding ROCKET Trial and SKY ROCKET Non-Interventional Data in Fragile X Expected by Early Q2 2020
OV935/TAK935 (soticlestat) in Rare Developmental and Epileptic Encephalopathies (DEE):
Data from Randomized Phase 2 ELEKTRA Trial in Children with Dravet Syndrome or Lennox-Gastaut Syndrome Expected in 2H 2020
Initial Data from Phase 2 ARCADE Trial in Dup15q Syndrome or CDKL5 Deficiency Disorder Expected in Q1 2020
Additional Clinical Data From ENDYMION Open Label Extension Study Expected in Q1 2020
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | GAMESTOP Hauptdiskussion | +23,87 % | |
2 | BIOXCEL THERAPEUT DL-,001 Hauptdiskussion | -7,91 % | |
3 | Hauptdiskussion über TUI Aktie | +6,91 % | |
4 | SUPER MICRO Hauptdiskussion | -3,00 % | |
5 | Nio für normale Kommunikation | -1,14 % | |
6 | Lilium Aktie | -2,68 % | |
7 | Novavax Hauptdiskussion | +19,99 % | |
8 | DAX Hauptdiskussion | -0,21 % | |
9 | Nantkwest / Immunitybio -> IBRX | -5,84 % | |
10 | Hexagon Purus | +8,50 % | Alle Diskussionen |
Anzeige
Aktien
|
Thema | ||
---|---|---|---|
1 | GAMESTOP Hauptdiskussion | +21,75 % | |
2 | BIOXCEL THERAPEUT DL-,001 Hauptdiskussion | -7,30 % | |
3 | Hauptdiskussion über TUI Aktie | +7,08 % | |
4 | SUPER MICRO Hauptdiskussion | -3,04 % | |
5 | Nio für normale Kommunikation | -1,14 % | |
6 | Lilium Aktie | -2,68 % | |
7 | Novavax Hauptdiskussion | +20,78 % | |
8 | Nantkwest / Immunitybio -> IBRX | -4,93 % | |
9 | Hexagon Purus | +8,50 % | |
10 | NVIDIA Hauptdiskussion | +3,32 % | Alle Diskussionen |